CellCentric wins Innovate UK award to expand use of p300/CBP inhibitors in cancer.November 8th 2016:CellCentric is developing first in class drug compounds against a key regulator of cancer. P300/CBP are twin (paralogue) histone acetyltransferase proteins, that act as transcriptional co-factors. When inhibited they cause the down regulation of the androgen receptor (AR) and its variants. It also decreases c-Myc, another key cancer driver.
CellCentric expands team to push forward to IND.February 9th 2016:CellCentric is developing proprietary anti-cancer compounds that target androgen receptor (AR) regulation. These hold promise for castrate resistant prostate cancer (CRPC) as well as other cancers. As the company moves towards Candidate selection and IND qualification, CellCentric is expanding its team for future activities.